Mineralys CMO Sells $569,809 in Stock While Exercising Options; Company Advances Lorundrostat Program
Mineralys Therapeutics Chief Medical Officer David Malcom Rodman sold 14,676 shares of the companys common stock for roughly $569,809 across February 12 and 13, 2026, while exercising options to acquire 14,056 shares valued at $102,340. The trades were executed under a Rule 10b5-1 plan adopted October 6, 2025. Separately, the companys lead candidat…